Nitrile Gloves, Not Ribbons

Every October, the noise starts up again: it’s breast cancer’s turn for awareness. I brace for it a little every year. What bothers me isn’t the concept, it’s watching companies race to out-pink each other.

A pink ribbon on a shirt or a car can foster a certain amount of solidarity, but at the corporate level, the awareness noise is genuinely inescapable: a building lit up pink for the night, a pink yogurt lid, or a player running out onto the field in pink cleats. Many companies have run some version of the same campaign, and what actually happens to the profit from pink merchandise varies wildly: modest percentages, hard caps on total donations, or numbers that only recently moved after enough people asked questions.

In addition to the question of money is the question of effect: what does a company’s participation do? If the goal actually is awareness, I’ve never understood who remains unaware. It tends to generate goodwill instead, and the sometimes cynical among us might call that marketing, whether or not that’s the intent.

Here’s a sentence that’s true to me, one most people have their own version of: my sister had breast cancer. One in eight women in the U.S. will hear that diagnosis in her lifetime (though women aren’t the only ones who get it). So we are aware. We have been aware for a long time.

At one point, however, we actually needed awareness, in the literal sense of the word. When the American Cancer Society started its breast cancer awareness campaign in 1985, breast cancer was a disease people didn’t discuss in polite company, self-exams weren’t routine, and mammograms weren’t the norm they are now. Getting people to talk about it, check themselves, and get screened was a real, specific goal, and awareness did its job at the time. Last year marked the campaign’s fortieth anniversary, a point at which even the American Cancer Society’s own retrospective pointedly admitted: awareness alone isn’t enough anymore.

October runs on that word, awareness, as if noticing something were the same as solving it. As if on November 1st, we can dust off our hands, congratulate ourselves, and move on to the next color of the month. But breast cancer research doesn’t run on that calendar. Real, promising work has been happening. Learning about it might not change anything either, not directly, but it’s one step closer to what the American Cancer Society itself is now calling “Turning Awareness Into Action.”

More Than a Pretty Face

This starts, perhaps unexpectedly, with the axolotl, a foot-long Mexican salamander known for its perpetual smile and the feathery gills that fan out from its head like a spray of coral. The most common pet-store variety is also, conveniently for this piece, pale pink. It has become plastered across backpacks, folders, plush toys, and t-shirts. My nine-year-old niece and her friends are obsessed with them.

Continue reading “Nitrile Gloves, Not Ribbons”

From Gum Disease to Breast Cancer: An Oral Bacterium’s Unexpected Journey

You’re sitting in the dentist’s chair, nodding along to the familiar flossing lecture you’ve been politely ignoring for most of your adult life. Fair enough. It’s hard to get excited about gum health. But it turns out your dentist may have been underselling the pitch.

A study published in January 2026 in Cell Communication and Signaling shows that a common gum disease bacterium can promote breast cancer growth and spread in mice, and the findings hint at a particularly troubling link for people carrying BRCA1 mutations (1). “Floss to help prevent cancer” probably wasnโ€™t on your 2026 bingo card, yet here we are.

Continue reading “From Gum Disease to Breast Cancer: An Oral Bacterium’s Unexpected Journey”

Growing Our Understanding of Triple-Negative Breast Cancer in Sub-Saharan Africa: Why Comprehensive Population Data Matters

A digitally rendered illustration of a cancer cell superimposed over the African continent. The cancer cell, with a textured, reddish-orange surface and extending tendrils, appears to spread across the dark red map of Africa, symbolizing the impact or presence of cancer on the continent.

In the genomics era, the promise of precision medicine and tailored diagnostics is only as good as the datasets, which makes it imperative that those sets reflect the diversity of the human population. Populations from the African continent, the most genomically diverse region in the world, are underrepresented in current genomic data sets.  Nowhere is closing this data gap more urgent than with triple-negative breast cancer (TNBC), which has a disproportionately high incidence in women of African descent and limited therapeutic options.

Highlighting why comprehensive population data is so important are the results of a recent study profiling of 30 TNBC tumor samples from Angola and Cape Verde (1).  Whole-exome sequencing (WES), enriched with untranslated regions (UTRs), showed that 86% of somatic variants in these samples had never been reported before. WES can be especially valuable when working with limited or degraded samples, such as the FFPE samples used in this study, because it allows you to gain valuable insights from samples that are impractical for whole-genome sequencing (WGS). This studyโ€™s results emphasize the value in expanding omics cancer research so that it includes all populations and areas of the genome.

Continue reading “Growing Our Understanding of Triple-Negative Breast Cancer in Sub-Saharan Africa: Why Comprehensive Population Data Matters”

Microfluidic Organoids Could Revolutionize Breast Cancer Treatment

Breast cancer is the most common tumor among women worldwide and has a profound impact on individuals and society. Aside from being a leading cause of cancer-related death, patients often undergo invasive treatments such as surgery, radiation, and chemotherapy, which may result in long-term side effects and reduced quality of life. Additionally, the healthcare burden of breast cancer is immense. This makes effective, timely, and personalized treatments a critical need.

A recent study published in Scientific Reports presents a microfluidic-based method for growing breast cancer organoids that significantly reduces the culture time while maintaining essential structural and drug response characteristics. This method could be the key to developing personalized breast cancer treatments in the future.

Continue reading “Microfluidic Organoids Could Revolutionize Breast Cancer Treatment”

Dynein Motor Proteins Could Be the Moving Power Behind Cancer Metastasis

3D Cancer Cell

โ€œThe cancer has spread.โ€ are perhaps some of the most frightening words for anyone touched by cancer. It means that cancer cells have migrated away from the primary tumor, invaded health tissues and firmed secondary tumors. Called metastasis, this event is the deadliest feature of any type of cancer (1). The cellular mechanisms that play a role in metastasis could serve as powerful therapeutic targets. Unfortunately, understanding of these mechanisms is limited. However, some studies have suggested a link between the dysregulation of microtubule motors and cancer progression. A new study by a team from Penn State has revealed that the motor protein dynein plays a pivotal role in the movement of metastatic breast cancer cells through two model systems simulating soft tissues (1).

Continue reading “Dynein Motor Proteins Could Be the Moving Power Behind Cancer Metastasis”

Improving Cancer Drug Screening with 3D Cell Culture

Differential contrast image of HCT116 colon cancer spheroid grown in a 96-well hanging-drop platform after seeding with 800 cells. Copyright Promega Corporation.
Differential contrast image of HCT116 colon cancer spheroid grown in a 96-well hanging-drop platform after seeding with 800 cells. Copyright Promega Corporation.
Tissue culture using primary or cultured cell lines has long been a mainstay of testing compounds for inhibiting cell growth or promoting apoptosis during screening for cancer drugs. However, the standard culture conditions result in monolayers of cells, dividing and growing across the bottom of a well, plate or flask in a single layer. The drawback of this technique is that organisms do not come in monolayers; a three-dimensional (3D) spheroid is closer to the in vivo state, especially if the spheroids are made up of more than one cell type like tumors in multicellular organisms. Even more beneficial would be using 3D cultured cells in high-throughput screening to facilitate compound profiling for target effectiveness and cytotoxicity. In a recent PLOS ONE article, researchers used normal and breast cancer cells both in monoculture and coculture to test a set of compounds and found results differed between 2D and 3D cultured cells. Continue reading “Improving Cancer Drug Screening with 3D Cell Culture”

Milk (Fat) Does a Body Good

One Milk Marketing Board campaign uses celebrities to promote its product by photographing them with milk moustaches. Glamour aside, selling cow’s milk is important to the livelihood of many farmers worldwide and generates a variety of well-appreciated products. What would pizza be without cheese? Summer without ice cream? Lunches without yogurt? Mashed potatoes without butter? Flammkuchen without crรจme fraiche? You can see where I am going with this. I live in Americaโ€™s Dairyland where people commonly drink milk with meals. I think there is nothing better than a cold glass of milk with a rich chocolate cake. However, the Milk Marketing Board has missed a significant finding: milk fats can attenuate metastasis and some of the systemic effects of cancer and chemotherapyโ€”at least in mice. Continue reading “Milk (Fat) Does a Body Good”

Does Your Daily Cup of Coffee Affect Your Risk of Cancer?

Coffee beansIs there an association between coffee consumption and incidence of cancer? The answer seems to depend on whom you ask, the study group involved, how much and what type of coffee the study participants drank and a host of other factors. Many research studies have found no link or only a weak link between the two, but recently a new study that showed a stronger association between coffee consumption and a lower risk of prostate cancer was published in the Journal of the National Cancer Institute (1). Why should we believe this new study when so many other studies have been unable to show a strong link?
Continue reading “Does Your Daily Cup of Coffee Affect Your Risk of Cancer?”